Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705326 | 0.79 | AKR1B1 (0.51) | AKR1B1 | |
| SCHEMBL23704862 | 0.74 | BACE1 (0.35) | BACE1AKR1B1 | |
| SCHEMBL23704774 | 0.74 | BACE1 (0.33) | BACE1AKR1B1PNMT | |
| SCHEMBL23715383 | 0.73 | AKR1B1 (0.38) | AKR1B1 | |
| SCHEMBL23705803 | 0.72 | BACE1 (0.34) | BACE1PNMT | |
| SCHEMBL23704976 | 0.72 | BACE1 (0.40) | BACE1PNMT | |
| SCHEMBL25497929 | 0.72 | BACE1 (0.34) | BACE1AKR1B1PNMT | |
| SCHEMBL23705344 | 0.71 | BACE1 (0.34) | BACE1PNMT | |
| SCHEMBL31367719 | 0.70 | BACE1 (0.40) | BACE1PNMT | |
| SCHEMBL23704964 | 0.68 | BACE1 (0.35) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115484948-A | Compound and use thereof | 福宏治疗公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-4096657-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | BACE1 3015/4885AKR1B1 2751/4885PNMT 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.